AXIOS (Tina Reed) - Moderna and Merck shares soar on mRNA cancer vaccine
Moderna and Merck shares soared on Wednesday after the companies said a personalized mRNA treatment hit its target of preventing skin cancer from recurring or spreading in a late-stage clinical trial. Why it matters: The results come at a pivotal moment for Moderna and mRNA research, after Trump administration health officials cut federal funding for new vaccines and asserted the technology poses more risks than rewards. - The customized therapy, which could see a commercial launch next year, could also be adapted for other cancers of the kidney, bladder and pancreas. The big picture: The results could lead to a remarkable turnaround for Moderna, whose market value plummeted more than 90% after demand for its COVID vaccine declined…
Moderna and Merck shares soared on Wednesday after the companies said a personalized mRNA treatment hit its target of preventing skin cancer from recurring or spreading in a late-stage clinical trial. Why it matters: The results come at a pivotal moment for Moderna and mRNA research, after Trump administration health officials cut federal funding for new vaccines and asserted the technology poses more risks than rewards. - The customized therapy, which could see a commercial launch next year, could also be adapted for other cancers of the kidney, bladder and pancreas. The big picture: The results could lead to a remarkable turnaround for Moderna, whose market value plummeted more than 90% after demand for its COVID vaccine declined…Open